Human Immune Globulin Intravenous Market
Human Immune Globulin Intravenous Market Scope:
Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Human Immune Globulin Intravenous Market Size and Growth
The Human Immune Globulin Intravenous (IVIG) market is experiencing robust growth, driven by rising autoimmune disorders and immune deficiencies. In 2023, the market size is estimated to exceed USD 10 billion, reflecting increased demand for effective therapies. Competitive dynamics and regulatory advancements continue to shape market conditions and opportunities for stakeholders.
Companies Covered
(Covid 19 Impact Covered)
◍ Takeda
◍ Grifols
◍ CSL
◍ Octapharma
◍ Biotest
◍ Kedrion
◍ Hualan Bio
◍ CNBG
◍ Shanghai RAAS
◍ CBPO
◍ LFB Group
◍ BPL
◍ Sichuan Yuanda Shuyang
The Human Immune Globulin Intravenous Market includes key players like Takeda, Grifols, CSL, and Octapharma, which develop and market therapies for immunodeficiencies and autoimmune diseases. Their innovations expand treatment options, enhance patient outcomes, and drive market growth. Key revenue highlights include Takeda ($9 billion) and Grifols ($5.8 billion).
Market Segmentation
By Application
Immunodeficiency
Autoimmune Disease
Acute Infection
Request Sample Report
By Product
IVIg Liquid
IVIg Powder
Market Growth
Request Sample Report
$ X Billion USD
